RIVASTIGMINE (rivastigmine) by Humanwell Pharmaceutical is cholinesterase inhibitors [moa]. Approved for dementia of the alzheimer's type (ad), mild-to-moderate dementia associated with parkinson's disease (pdd). First approved in 2019.
Drug data last refreshed 20h ago
Cholinesterase Inhibitors
Cholinesterase Inhibitor
Worked on RIVASTIGMINE at Humanwell Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia